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Abstract
Background: Postpartum haemorrhage (PPH) is a major cause of maternal morbidity and mortality and its incidence is
increasing in many countries despite management guidelines. A national quality improvement programme called the
Obstetric Bleeding Strategy for Wales (OBS Cymru) was introduced in all obstetric units in Wales. The aim was to
reduce moderate PPH (1000mL) progressing to massive PPH (> 2500mL) and the need for red cell transfusion.
Methods: A PPH care bundle was introduced into all 12 obstetric units in Wales included all women giving birth in
2017 and 2018 (n = 61,094). The care bundle prompted: universal risk assessment, quantitative measurement of blood
loss after all deliveries (as opposed to visual estimation), structured escalation to senior clinicians and point-of-care
viscoelastometric-guided early fibrinogen replacement. Data were submitted by each obstetric unit to a national
database. Outcome measures were incidence of massive PPH (> 2500mL) and red cell transfusion. Analysis was
performed using linear regression of the all Wales monthly data.
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Results: Uptake of the intervention was good: quantitative blood loss measurement and risk assessment increased to
98.1 and 64.5% of all PPH > 1000mL, whilst ROTEM use for PPH > 1500mL increased to 68.2%. Massive PPH decreased
by 1.10 (95% CI 0.28 to 1.92) per 1000 maternities per year (P = 0.011). Fewer women progressed from moderate to
massive PPH in the last 6 months, 74/1490 (5.0%), than in the first 6 months, 97/1386 (7.0%), (P = 0.021). Units of red
cells transfused decreased by 7.4 (95% CI 1.6 to 13.2) per 1000 maternities per year (P = 0.015). Red cells were
transfused to 350/15204 (2.3%) and 268/15150 (1.8%) (P = 0.001) in the first and last 6 months, respectively. There was
no increase in the number of women with lowest haemoglobin below 80 g/L during this time period. Infusions of
fresh frozen plasma fell and there was no increase in the number of women with haemostatic impairment.
Conclusions: The OBS Cymru care bundle was feasible to implement and associated with progressive, clinically
significant improvements in outcomes for PPH across Wales. It is applicable across obstetric units of widely varying size,
complexity and staff mixes.
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Background
Bleeding after childbirth (postpartum haemorrhage,
PPH) is the leading cause of maternal death world-
wide [1]. In resource rich countries PPH causes 80%
of severe maternal morbidity and its incidence is in-
creasing in many regions [2, 3], including Wales [4],
despite international guidance [5–7]. In the UK PPH
is described as moderate at 1000 mL blood loss and
severe at 2000 mL [6]. Massive PPH is defined as >
2500 mL and, in resource rich countries, is associated
with a hysterectomy rate of 6% and intensive care ad-
mission in 11.8% of cases [3]. Post-traumatic stress
disorder is common after PPH [8]. Multi-professional
management of PPH requires the skills of midwives,
obstetricians, anaesthetists, healthcare support staff
and haematologists working in an effective team. Var-
iations in care are widely reported, with delays in es-
calation to senior staff a common theme [9, 10]. A
recent confidential enquiry identified deficiencies in
care, compared to guidelines, in 90% of cases [11].
Postpartum haemorrhage may be exacerbated by
haemostatic impairment. A Clauss fibrinogen below 2 g/L
is associated with progression of bleeding [12, 13], al-
though clinically significant deficiencies of other clotting
factors and platelets are less common [14–16]. In severe
PPH, laboratory coagulation results are often too slow to
be useful clinically and guidelines recommend the use of
empirical treatment with fixed ratios of red blood cells
(RBC), fresh frozen plasma (FFP) and platelets, based on
data derived from major trauma [5, 6]. This results in
many women receiving blood components when haemo-
stasis is normal [17]. Point-of-care haemostasis test re-
sults, using viscoelastometry, are available within 10min
and can direct timely and targeted replacement of fibrino-
gen and avoid unnecessary FFP during PPH [15, 18–20].
International PPH quality improvement projects have
been undertaken with the aim of standardising care and
improving outcomes. Interventions have included risk
assessment, quantitative measurement of blood loss and
escalation to senior clinicians, although to date all have
used empirical, fixed-ratio transfusion therapy [21–24].
OBS Cymru is a national quality improvement project
developed by combining lessons learnt during 10-years
of research [17] with themes emerging from inter-
national PPH quality improvement projects [21–24].
OBS Cymru introduced an integrated care bundle into
all obstetric units in Wales [25]. A key and unique fea-
ture was the inclusion of viscoelastometric point-of-care
haemostatic tests to guide targeted blood component ad-
ministration [15, 18–20]. We report the impact of OBS
Cymru over a 2-year period.
Methods
Intervention
Launched in November 2016, OBS Cymru introduced a
PPH care bundle between January and April 2017 into
all 12 obstetric units in Wales. These obstetric units sup-
port between 500 and 6000 births per year, with about
31,000 births across Wales. The lead research and devel-
opment office designated OBS Cymru as a quality im-
provement project and service evaluation according to
NHS guidance. Consequently ethical approval and indi-
vidual consent to collect and report data was not
required.
The design, initiation and project interventions have
been described in detail previously [25]. OBS Cymru
funding provided a Rotem Sigma® point-of-care coagula-
tion device (Instrumentation Laboratories, Werfen, Bar-
celona, Spain) for use in each obstetric unit. The
intervention promoted:
1. Risk assessment of all mothers admitted to delivery
suite. The risk assessment tool is available [26].
2. Quantitative measurement of blood loss from
delivery using volumetric and gravimetric
techniques for all births as opposed to visual
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estimation. Details of the method and validation
data supporting quantitative measurement have
been published [4, 25, 27].
3. Escalation of care to senior clinicians, if not already
involved, at specified volumes of blood loss. An
obstetrician, senior midwife and anaesthetist were
required to attend the mother at 1000 mL, at the
latest, and a consultant obstetrician and anaesthetist
informed at 1500 mL.
4. Point-of-care tests of haemostasis were taken at
1000 mL or earlier for clinical concern. If required,
targeted, early replacement of fibrinogen was
administered following a published algorithm [26].
Tranexamic acid was infused as soon as abnormal
bleeding was recognised and repeated if bleeding
continued [28].
The intervention was intended for all births and was
not limited to those complicated by abnormal bleeding.
It was underpinned by a standardised paperwork pro-
forma that prompted management and created a con-
temporaneous record of findings and actions [26]. An all
Wales guideline reinforced the intervention and standar-
dised obstetric management including uterotonic use
[29]. Antenatal anaemia, cell salvage and transfusion pol-
icies were unchanged throughout the project.
The Rotem point-of-care coagulation devices were
supported by a validated algorithm [15, 17, 18, 26] and
were compliant with internal and external quality assur-
ance. A minor revision of the Rotem interpretation algo-
rithm was introduced in 2018 to emphasise the
importance of correcting hypofibrinogenaemia before
considering FFP [26]. Haemostatic impairment was de-
fined as fibrinogen < 2 g/L, Fibtem A5 < 12mm or PT or
aPTT > 1.5 times normal [6, 30] (equating to PT > 16 or
aPTT > 50 s). In autumn 2018 all Rotem devices received
a hardware update which was associated with slightly
lower Fibtem A5 measurements, the blood product
algorthim was not adjusted.
The national team co-ordinated multi-professional
training at each unit, as described [25], this training was
front-loaded at the start of the project with top-up train-
ing throughout the 2 year period. A lead midwife, obstetri-
cian, anaesthetist and haematologist were appointed at
each site to support ongoing training and oversee the pro-
ject locally with the midwifery time funded by the project.
The intervention was introduced during the first 6 month
period (January to June 2017) and integrated into standard
care obstetric units throughout 2017 and 2018. Training
covered quantitative measurement of blood loss, escal-
ation of care and interpretation of Rotem results. The
OBS Cymru principles were integrated into PROMPT
(PRactical Obstetric Multi-Professional Training) for
Wales to support sustainability [31]. Annual multi-
professional national meetings allowed dissemination of
learning and sharing of good practice.
Data sources
The Welsh Maternity Indicators Dataset (NHS Wales
Informatics Service) provided data regarding number of
births and mode of delivery. An all Wales OBS Cymru
database was established by Improvement Cymru.
Women experiencing bleeds ≥1000mL or in whom
there was concern about abnormal bleeding had a lim-
ited dataset collected. Women with bleeds ≥1500mL or
who received a transfusion had more detailed informa-
tion collected (supplementary Figure 1).
In addition, five audits were undertaken to establish
the uptake of measured blood loss and use of the paper-
work proforma and the risk assessment tool. Audits in-
cluded up to 30 consecutive women from each obstetric
unit, irrespective of blood loss. Individual units were en-
couraged to advertise the audit and allow the midwife
caring for the patient to contribute data following deliv-
ery. Audit data was provided by all 12 obstetric units in
October 2016 (n = 510, before OBS Cymru started), June
2017 (n = 455) and June 2018 (n = 492), from 11 units in
December 2017 (n = 405), and from 7 units in December
2018 (n = 259).
Anonymous patient surveys were performed in 2017
(June–December) and 2018 (September). Local teams
circulated forms to women experiencing PPH ≥1000mL.
Questions explored communication with the mother
and her family and areas for improvement in care. A
staff questionnaire was circulated to local leadership
teams between September and December 2018 to aid
understanding of how OBS Cymru had changed local
practice.
Analysis
Data are summarised descriptively with continuous vari-
ables reported as median, inter-quartile range (IQR) and
range and categorical variables as number and percent
or per 1000 maternities. Descriptive data were reported
in four 6-month periods between January 2017 and De-
cember 2018 to show changes across time. The interven-
tion was being implemented during January to June
2017 and this time period is compared to the last 6
month period, after the intervention had been adopted,
in some analyses. This comparison was chosen to reflect
project uptake and prior to any analyses being per-
formed. In addition, an interrupted time series analysis
was performed to investigate the trend of bleeds ≥2500
mL before and after the intervention was introduced.
Changes in the proportion of women experiencing
massive PPH, the number of units of RBC transfused
and intensive care admission were analysed by linear re-
gression using the all Wales monthly data. A simple
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linear relationship was found to be the best model, with
higher-order terms not leading to any substantial im-
provements in the model. The dependent variables were
PPH ≥2500 mL, units of RBC transfused in Wales and
episodes of intensive care and the independent variable
was months in each case. Estimates are reported with
95% confidence intervals (CI). Sensitivity analyses using
quasi-Poisson regression models with total maternities
as offset provided very similar results. Chi square test
was used to compare events in the first and last 6 month
periods. Audit results are presented as the percentage of
cases where individual interventions were performed
with box plots illustrating completion of all components.
Funnel plots were used to indicate variations between
units. Data were analysed using SPSS version 23, R ver-
sion 3.6.0 and ggplot2 version 3.2.0.
Results
Demographics
Between 1st January 2017 and 31st December 2018, 61,
094 women gave birth in Wales. Mode of delivery was
unassisted vaginal for 62.6%, instrumental vaginal 9.5%,
emergency caesarean section 14.4% and non-emergency
caesarean section 13.5%. There were 6024 episodes
(98.6/1000 maternities) recorded on the OBS Cymru
database because of PPH ≥1000 mL or clinical concern
of abnormal bleeding. The number of episodes increased
during the project, possibly because of better recognition
of total blood loss as quantitative measurement replaced
visual estimation (Table 1). For PPH ≥1500mL, 2209 ep-
isodes (36.2/1000 maternities) were reported. The mode
of delivery, causes of bleeding and first recorded haemo-
globin (Hb) and Clauss fibrinogen remained constant
throughout (Table 1).
Uptake of OBS Cymru intervention
Uptake increased for all components of the OBS Cymru
intervention at all sites. Uptake increased progressively
across the 2 year period (Table 1 and Fig. 1). Quantita-
tive blood loss measurement increased from 83 to 98%
for PPH ≥1000mL and Rotem analysis increased from
38 to 68% of episodes with ≥1500mL blood loss. The
proportion of women receiving treatment that was com-
pliant with the blood component algorithm increased
from 19 to 68% (Table 1). Audit data of consecutive
women, irrespective of blood loss volume, showed the
variation between sites in the percentage of maternities
where blood loss was measured, risk assessment per-
formed and standardised paperwork used (Fig. 1).
Severity of postpartum haemorrhage
Incidence of massive postpartum haemorrhage
Massive PPH (blood loss > 2500mL) fell from 6.4 to 4.9/
1000 maternities between the first and last 6 month
periods (Table 2). Regression analysis suggested a pro-
gressive fall across the 24 month period with an esti-
mated decrease in massive PPH of 1.10 (95% CI 0.28 to
1.92)/1000 maternities/year (P = 0.011) (Fig. 2a). The in-
cidence of massive PPH at each obstetric unit during the
first and last 6 months is shown in Fig. 2b and c. These
illustrate the overall decrease in massive PPH in Wales
and a reduction in the number of obstetric units with
massive haemorrhage rates above 10/1000 maternities.
More detailed obstetric unit level data are shown in sup-
plementary material Table 1. Information about the inci-
dence of massive PPH in Wales before and after OBS
Cymru is shown as an interrupted time series analysis in
supplementary Figure 2 demonstrating a statistically sig-
nificant change in the trend of massive haemorrhage.
The all Wales incidence of PPH ≥1000 mL increased,
PPH ≥1500 mL remained stable and ≥ 2000 mL fell
slightly (Table 2) throughout the 2 year period. The ratio
of moderate PPH (1000 mL) vs massive PPH (> 2500
mL) fell throughout the 2 year period; in the first 6
months, 97/1386 (7.0%), second 6months 92/1480
(6.2%), third 6 months 76/1412 (5.3%) and last 6 months,
74/1490 (5.0%) (P = 0.021 comparing first and last 6
months).
Intensive care admission, hysterectomy and length of
hospital stay
The estimated decrease in intensive care admission was
0.31 (95% CI: − 0.21–0.84)/1000 maternities/year (P =
0.23). The total time spent in intensive care fell but this
was due mainly to a prolonged stay of 168 h for one
woman in the first 6 months (Table 2). There were 22
hysterectomies in total (0.36/1000 maternities), of which
19 were associated with PPH (0.31/1000) (Table 2). Of
these hysterectomies, 11/19 (58%) were for placenta
accreta, increta or praevia and are likely to represent ap-
propriate care [6, 7] The eight hysterectomies for PPH
that were unrelated to abnormal placentation occurred
at 0.13, 0.06, 0.27 and 0.07/1000 maternities in each 6
month period. These numbers are too small for mean-
ingful comparison. The length of hospital stay for
women with PPH ≥1500mL was similar throughout
(Table 2).
Transfusion of red blood cells and blood components
The proportion of women transfused RBCs for PPH fell
from 350/15204 (2.3%) to 268/15150 (1.8%) between the
first and last 6 month periods, (P = 0.0010). The total
number of units of RBCs transfused in Wales fell from
54.1 to 40.2/1000 (Table 3). Regression analysis esti-
mated that the number of units of RBCs transfused for
PPH fell by 7.4 (95% CI 1.6–13.2)/1000 maternities/year,
P = 0.015 (Fig. 3a and Table 3). The total number of
units of RBC/1000 maternities transfused at each
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Total number of maternities in Wales 15,204 15,986 14,754 15,150
Episodes with ≥ 1000mL blood loss or clinical concern of abnormal bleeding N (/1000
maternities)
1448 (95.2) 1519 (95.1) 1499 (101.6) 1558 (102.8)
Episodes with ≥ 1500mL blood loss N (/1000 maternities) 547 (36.0) 588 (36.8) 530 (35.9) 544 (35.9)
Mode of delivery
Unassisted vaginal: n (%) 211 (38.6) 228 (38.8) 203 (38.3) 184 (33.8)
Instrumental vaginal: n (%) 115 (21.0) 116 (19.7) 123 (23.2) 147 (27.0)
Non-emergency caesarean section: n (%) 181 (33.1) 194 (33.0) 170 (32.1) 161 (29.6)
Emergency caesarean section: n (%) 40 (7.3) 50 (8.5) 34 (6.4) 51 (9.4)
Not recorded: n (%) 0 (0) 0 (0) 0 (0) 1 (0.2)
Cause of bleeding for episodes with ≥ 1500mL blood loss N (%) (NB many bleeds had multiple causes)
Uterine atony 323 (59.0) 352 (59.9) 276 (52.1) 315 (57.9)
Surgery related 142 (26.0) 142 (24.1) 135 (25.5) 161 (29.6)
Genital tract trauma 175 (32.0) 185 (31.5) 178 (33.6) 189 (34.7)
Extragenital bleeding only 6 (1.1) 1 (0.2) 12 (2.3) 5 (0.9)
Uterine rupture 4 (0.7) 4 (0.7) 1 (0.2) 0 (0.0)
Placenta praevia 16 (2.9) 8 (1.4) 15 (2.8) 10 (1.8)
Placenta accrete 5 (0.9) 7 (1.2) 5 (0.9) 5 (0.9)
Amniotic fluid embolus 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0)
Uterine inversion 1 (0.2) 1 (0.2) 0 (0.0) 1 (0.2)
Placental abruption 17 (3.1) 14 (2.4) 17 (3.2) 23 (4.2)
Retained products 63 (11.5) 46 (7.8) 57 (10.8) 45 (8.3)
No cause reported 1 (0.2) 0 (0.0) 1 (0.2) 0 (0.0)
First blood test after recognition of haemorrhage for PPH ≥ 1500mL
















Uptake of OBS Cymru intervention
Risk assessment completed. All Wales: n (% of all episodes ≥1000 mL)a 23 (1.6) 399 (26.2) 931 (62.1) 1003 (64.4)

























Blood loss quantitatively measured All Wales: n (% of all episodes ≥1000 mL) 1204 (83) 1409 (93) 1404 (93.7) 1530 (98.2)












Rotem analysis performed: n (% of episodes with bleeds ≥1500 mL) 206 (37.7) 346 (58.8) 380 (71.7) 371 (68.2) b












Rotem analysis requiring intervention and acted on according to
algorithm: n (% of episodes with bleeds > 1500 mL)
3/16 (19) 18/35 (51) 19/29 (65) 25/37 (68) b
Legend a:One obstetric unit did not report any data for this intervention and has been excluded from the analysis and btwo obstetric units did not
return Rotem data between July and December 2018. A more complete dataset was collected for PPH ≥1500 mL and so Rotem analyses and laboratory
results are only reported for these cases
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obstetric unit in the first and last 6 months of the project
is shown in Fig. 3b and c. The number of obstetric units
that transfused ≥50 units of RBC per 1000 maternities
fell from 8/12 to 3/12 (P = 0.041). Despite the reduction
in RBC transfusions, the proportion of women with a
lowest Hb < 80 g/L did not increase (Table 3).
The proportion of women receiving FFP fell by 42%
(P = 0.088) and the use of fibrinogen concentrate in-
creased by 37% (P = 0.26) between the first and last 6
months (Table 3). The decrease in FFP usage occurred
mainly in the final 6 months after clinicians had been en-
couraged to correct fibrinogen before infusing FFP [26].
Infusion of cryoprecipitate and platelets was very un-
common (Table 3).
Haemostatic impairment
The number of laboratory coagulation tests reported in-
creased over time and so differences between 6month
periods must be interpreted with caution. Despite this,
the restrictive use of FFP was not associated with an in-
crease in haemostatic impairment as demonstrated by
the lowest fibrinogen and the longest PT/aPTT (Table
3). The median Fibtem A5 was 3 mm lower and more
women had a Fibtem A5 < 12 mm in the last 6 months,
this is discrepant to the laboratory fibrinogen results and
probably reflects the change in Fibtem A5 after the
Rotem devices were updated. This may have affected the
number of women receiving fibrinogen concentrate
which increased in the last 6 months (Table 3).
Maternal and staff feedback
Results of the patient survey undertaken in 2017 have
been reported [25]. Eight obstetric units collected 47 pa-
tient surveys in September 2018, mean (range) blood
loss 1716 (1029–5743) mL (data was unavailable regard-
ing the survey response rate). In total 66% of women
Fig. 1 Uptake of OBS Cymru interventions. Legend: The data indicate the percentage of cases where interventions were performed in consecutive
women, irrespective of blood loss. Box plots with median, interquartile range and range refer to the combination of paperwork being present in the
notes, the risk assessment having been completed and measured blood loss being performed
Table 2 PPH volume, admission to intensive care, hysterectomy and length of stay
Jan-Jun 2017 Jul-Dec 2017 Jan-Jun 2018 Jul-Dec 2018
PPH ≥1000 mL: n (/1000 maternities) 1386 (91.2) 1480 (92.6) 1412 (95.7) 1490 (98.3)
PPH ≥1500 mL: n (/1000 maternities) 547 (36.0) 588 (36.8) 530 (35.9) 544 (35.9)
PPH ≥2000 mL: n (/1000 maternities) 228 (15.0) 232 (14.5) 228 (15.5) 209 (13.8)
PPH ≥2500 mL: n (/1000 maternities) 97 (6.4) 92 (5.8) 76 (5.2) 74 (4.9)
Admission to intensive care for PPH: n (/1000 maternities) 10 (0.66) 12 (0.75) 9 (0.61) 6 (0.40)
Hours in intensive care for PPH: n (/1000 maternities) 322.3 (21.2)a 290 (18.1) 180 (12.2) 124 (8.2)
Hysterectomy associated with PPH: n (/1000 maternities) 5 (0.33) 3 (0.19) 8 (0.54) 3 (0.20)








Legend: The number of PPHs (/1000 maternities) between 1000 and 1499 mL was 55.2, 55.7, 59.8 and 62.4 in each six-month period. a one woman spent 168 h on
intensive care between January and June 2017
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remembered being told that they were having abnormal
bleeding and although 95% (39/41) felt well supported
during the PPH, 29% (8/28) said that care could have
been improved and better communication with mother
and partner was suggested. No mother reported that the
process of measuring blood loss or the escalating the
multi-professional team response to her bleeding had a
negative impact on the birth experience.
Local leadership staff survey, response rate 29/46
(63%), reported that OBS Cymru had changed individual
and unit level management of PPH. Table 4 shows the
components of the intervention that clinicians thought
had led to change.
Discussion
OBS Cymru was a national quality improvement project
that aimed to reduce morbidity associated with PPH by
introducing a care bundle into all 12 obstetric units in
Wales. There were clinically and statistically significant
reductions in massive haemorrhage across Wales with a
29% fall in the number of women progressing from
moderate to massive PPH. The number of women ex-
posed to RBC transfusion fell by 22% and the number of
units of RBC transfused for PPH decreased by 26%.
Adoption of the whole care bundle progressively im-
proved throughout the project with quantitative blood
loss measurement approaching 100% during the last 6
months. This technique is more accurate than visual es-
timation, which tends to under-report actual volume, es-
pecially for large bleeds [32–37]. The increase in bleeds
≥1000mL is likely to be a consequence of relative
under-reporting during the early stages of OBS Cymru
when quantitative measurement was being introduced.
Similarly, recognition of massive haemorrhage is likely
to have improved over time and so the reduction in the
rate of PPHs ≥2500mL may be an under-estimate.
The main strength of this report is that it represents
service change implemented across an unselected real-
world national cohort of women. It includes all women
giving birth in Wales and all obstetric units irrespective
of size, case mix and staffing levels. Women who gave
birth in the community and experienced bleeding were
transferred to an obstetric unit and are included in the
results. The improvements in outcomes are internally
consistent and continued throughout the project. The
population, mode of delivery and cause of bleeding are
similar to many high resource countries making the re-
sults widely applicable.
This report describes the changes observed over the
course of the project and it cannot be known for certain
that the improved outcomes were the result of the care
bundle. However, improvements of the size observed are
very unlikely to have happened simultaneously in multiple
centres by chance and progressive improvement in
Fig. 2 Change in incidence of postpartum haemorrhage > 2500 mL during OBS Cymru. Legend: Panel a shows the monthly rates for massive
haemorrhage and the fitted regression line with 95% confidence interval shaded in grey. Funnel plots show the incidence of massive postpartum
haemorrhages at each obstetric unit in the first (b) and last (c) 6 month periods of the quality improvement project. The line represents the mean
and the limits shown are 2 and 3 standard deviations. The dashed line indicates a massive haemorrhage rate of 10/1000 maternities
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outcomes coincided with the progressive adoption of the
intervention. The largest improvements in massive haem-
orrhage occurred in obstetric units with high initial rates
possibly, in part, due to regression towards the mean.
The blood component algorithm emphasised early
treatment of hypofibrinogenaemia in line with previous
studies and guidelines [5, 6, 12, 15, 18, 20, 38]. In the
last 6 month period the Rotem devices had a hardware
update associated with a fall in median Fibtem.
Clinicians should be wary of variations between and
within point-of-care devices and engage local laboratory
expertise and monitor local normal ranges [19].
Quantitative measurement of blood loss alone does
not improve outcomes [39]. However, when integrated
into a care bundle such as OBS Cymru, real time accur-
ate knowledge of blood loss acts as an enabler to prompt
teams to escalate care according to guidelines [6, 38].
The changes in massive haemorrhage and concurrent
Table 3 Transfusion and haematological results for postpartum haemorrhage
Jan-Jun 2017 Jul-Dec 2017 Jan-Jun 2018 Jul-Dec 2018
Transfusion of red blood cells and blood components
Number of women transfused red blood cells: n (/1000
maternities)
350 (23.0) 270 (16.9) 278 (18.8) 268 (17.7)
Total number of units of red blood cells transfused: n (/1000
maternities)
823 (54.1) 656 (41.0) 636 (43.1) 609 (40.2)
Number of women transfused ≥5 units red blood cells: n
(/1000 maternities)
16 (1.1) 14 (0.9) 14 (1.0) 11 (0.7)
Number of women transfused FFP: n (/1000 maternities) 26 (1.7) 20 (1.3) 21 (1.4) 15 (1.0)
Total number of units of FFP transfused: n (/1000 maternities) 87 (5.7) 78 (4.9) 74 (5.0) 37 (2.4)
Number of women transfused fibrinogen: n (/1000 maternities) 22 (1.5) 19 (1.2) 17 (1.2) 30 (2.0)
Total number of grams of fibrinogen transfused: n (/1000
maternities)
94 (6.2) 103 (6.4) 89 (6.0) 137 (9.0)
Number of women transfused cryoprecipitate: n (/1000
maternities)
6 (0.4) 3 (0.2) 2 (0.1) 5 (0.3)
Total number of units of cryoprecipitate transfused: n (/1000
maternities)
14 (0.9) 8 (0.5) 4 (0.3) 9 (0.6)
Number of women transfused platelets: n (/1000 maternities) 12 (0.79) 8 (0.50) 6 (0.41) 7 (0.46)
Total number of units of platelets transfused: n (/1000
maternities)
20 (1.3) 13 (0.8) 10 (0.7) 9 (0.6)
Haematological results
Lowest Clauss fibrinogen results: Med (IQR), range 4.2 (3.4–5), 0.3–9.2 4.1 (3.4–4.8), 0.5–
8.1
4.2 (3.5–4.7), 0.3–8 4.2 (3.5–4.8), 0.3–
9.8
Number with lowest fibrinogen ≤2 g/L n/reported results (% of
reported results)
24/383 (6.3) 18/399 (4.5) 17/435 (3.9) 22/459 (4.8)








Number with longest PT > 16 s n/reported results (% of
reported results)
5/384 (1.3) 5/388 (1.3) 5/434 (1.2) 4/458 (0.9)








Number with longest aPPT > 50 s n/reported results (% of
reported results)
4/384 (1.0) 3/388 (0.8) 2/435 (0.5) 0/458 (0.0)
Lowest Fibtem A5 results: Med (IQR), range 21 (18–25), 4–49 21 (17–24), 2–63 22 (19–25), 2–55 18 (16–21), 0–60
Number with lowest Fibtem A5 < 12 mm n/reported results (%
of reported results)
14/205 (6.8) 26/344 (7.6) 23/378 (6.1) 30/369 (8.1)
Longest Extem CT results: Med (IQR), range 57 (52–62), 17–120 57 (52–63), 38–147 56 (52–61), 30–300 55 (51–61), 11–481
Number with longest Extem CT > 75 s n/reported results (% of
reported results)
8/205 (3.9) 15/344 (4.4) 19/378 (5.0) 9/369 (2.4)




88 (78–98), 47–137 88 (79–100), 52–
137
Number with lowest haemoglobin < 80 g/L n/reported results
(% of reported results)
55/203 (27.1) 99/327 (30.3) 82/353 (23.2) 55/306 (18.0)
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uptake of OBS Cymru interventions suggest that meas-
uring blood loss and using Rotem, facilitated by multi-
professional team attendance at the bedside, were im-
portant factors. This was supported by feedback from
clinicians, with blood loss measurement, team working
and point-of-care coagulation tests stated to be the most
influential changes to practice.
The rate of hysterectomy for PPH remained low
throughout the project (0.31/1000 maternities). Consider-
ation of early hysterectomy in cases of abnormal placenta-
tion is advocated by guidelines and 58% of hysterectomies
were reported to have abnormal placental implantation [6,
7]. Other studies report a hysterectomy rate of 0.6–1/1000
maternities [3, 21] demonstrating that hysterectomies
were uncommon in Wales before OBS Cymru and this
may explain why improvements were not seen.
The number of women transfused RBCs for PPH fell
by 22%, equivalent to about 160 women in Wales avoid-
ing transfusion annually. RBC transfusion fell to 40
units/1000 maternities compared to a UK average of
about 100 units/1000 maternities. Despite this, the low-
est Hb during a PPH was similar throughout the 2 year
period and the proportion of women with Hb below 80
g/L did not increase, suggesting the reduction in transfu-
sion reflected reduced bleeding rather than withholding
RBCs inappropriately. Treatment of antenatal anaemia
Fig. 3 Change in incidence of red blood cell transfusion during OBS Cymru. Legend: Panel a shows the monthly rates for red blood cell
transfusion and the fitted regression line with 95% confidence interval shaded in grey. Funnel plots show the incidence of RBC transfusion for
postpartum haemorrhages at each obstetric unit in the first (b) and last (c) 6 month periods of the quality improvement project. The line
represents the mean and the limits shown are 2 and 3 standard deviations. The dashed line represents a RBC transfusion rate of
50 units/1000 maternities
Table 4 Contribution of intervention to practice change during OBS Cymru
Intervention Importance to practice change, n = 29
(1- not important, 5- most important)
Median (IQR)
Quantitative measurement of blood loss 5 (4–5)
Team working 5 (3–5)
Point-of-care testing of coagulation 5 (3–5)
Paperwork proforma 4 (1–4)
Legend: Responses were 37.9% midwifery, 37.9% anaesthesia, 17.2% obstetrics, 6.9% haematology. Free text responses describing changes in individual practice
included ‘awareness of ongoing blood loss’, ‘proactive rather than reactive’, ‘consistent management’, ‘appropriate product administration’, ‘communication and
team-working’. Barriers to implementation were reported by 69% (20/29) with the most common theme being training (70%, 14/20). This was also the leading
response for overcoming barriers 53.5% (8/15)
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was consistent throughout the project supported by the
finding that the first recorded Hb remained unchanged
across the 2 year period.
RBCs, FFP and platelets are often transfused in fixed-
ratios for major PPH [5, 6, 21, 24, 40–43] based on data
derived from major trauma [44, 45] PPH differs from
major trauma because at term women have an expanded
circulating blood volume and are hypercoagulable [46, 47]
and can maintain adequate haemostasis despite moderate
blood loss [15, 16]. Clinically significant deficiency of co-
agulation factors other than fibrinogen is uncommon in
PPH and fixed-ratio transfusion algorithms may result in
women receiving FFP with normal coagulation [17]. In
OBS Cymru PT/aPTT > 1.5 times normal was seen in 1%
of women experiencing a PPH ≥1500mL whilst fibrinogen
< 2 g/L occurred in about 5%, consistent with other stud-
ies [13, 15, 16] In OBS Cymru Extem clot time was used
to guide FFP infusion, with a 42% reduction in women re-
ceiving FFP. This occurred mainly in the last 6months
after the importance of correcting hypofibrinogenaemia
before FFP administration was emphasised. During this
time fewer women had PT/aPTT > 1.5 times normal dem-
onstrating that conservative use of FFP during PPH,
guided by point-of-care tests, does not increase haemo-
static impairment [15].
Other large-scale quality improvement projects for
PPH have combined risk assessment, measured blood
loss, standardised escalation and empirical, as opposed
to targeted, blood component resuscitation [21, 22,
24]. These initiatives have shown that, with high
adoption of the interventions, severe morbidity can be
reduced [21]. Sites adopting The California Maternal
Quality Care Collaborative care bundle reported a
21% reduction in severe maternal morbidity [24]. The
Association of Women’s Health, Obstetric, and Neo-
natal Nurses PPH Project implemented a care bundle
into 58 hospitals over 18 months. There was variable
uptake and no statistically significant difference in
maternal morbidity [22]. The lack of dedicated multi-
professional time was identified as a barrier. The use
of multi-professional leadership teams in OBS Cymru,
embedded at both a local and national level, with
dedicated time to lead change, contributed to the
speed, uptake and success of the project.
The integrated care bundle introduced universal risk as-
sessment to identify mothers of increased risk of PPH, whilst
quantitative measurement of blood loss enabled early recog-
nition of abnormal bleeding and progression. This facilitated
escalation to more experienced midwives and obstetricians
to treat the underlying cause of bleeding earlier whilst anaes-
thetists focused on timely resuscitation. Point-of-care tests
identified cases of hypofibrinogenaemia, allowing targeted
and rapid correction of coagulopathy whilst avoiding in-
appropriate FFP in the majority. Early identification of
normal coagulation facilitated escalation of obstetric mea-
sures to control bleeding.
Conclusions
A care bundle for the management of PPH, that in-
cluded point-of-care tests of coagulation to guide the
treatment of coagulopathy, was introduced as a national
quality improvement project involving more than 30,000
maternities annually. Clinically significant improvements
in PPH outcomes, including rates of massive haemor-
rhage and RBC transfusion are achievable on a national
level using quality improvement methodology. Obstetric
units of all size and case mix implemented and benefit-
ted from the care bundle with improved national out-
comes. These results suggest that trends towards
increasing incidence of severe PPH seen over recent
years can be reversed by structured multi-professional
team interventions. A cluster randomised trial is needed
to investigate whether the OBS Cymru care bundle im-
proves outcomes for PPH compared to standard care.
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